Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Sponsor:

National Cancer Institute (NCI)

Code:

NCT03866382

Conditions

Bladder Adenocarcinoma

Bladder Clear Cell Adenocarcinoma

Bladder Mixed Adenocarcinoma

Bladder Neuroendocrine Carcinoma

Bladder Small Cell Neuroendocrine Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Bone Scan

Cabozantinib S-malate

Computed Tomography

Ipilimumab

Magnetic Resonance Imaging

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information